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Abstract
Background: Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and
in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with
other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic
activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on
the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for
metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly.
Reoviruses have been shown to associate with microtubules and may require this association for efficient viral
replication.
Methods: The effects of reovirus and chemotherapy on in vitro cytotoxicity were investigated in PC3 and Du 145
cells and the interactions between agents were assessed by combination index analysis. An Annexin V/propidium
iodide fluorescence-activated cell sorting-based assay was used to determine mode of cell death. The effects of
reovirus and docetaxel administered as single agent or combination therapy were tested in vivo in a murine
model. The effects of docetaxel and reovirus, alone and together, on microtubule stabilisation were investigated by
Western blot analysis.
Results: Variable degrees of synergistic cytotoxicity were observed in PC3 and Du 145 cells exposed to live reovirus
and several chemotherapy agents. Combination of reovirus infection with docetaxel exposure led to increased late
apoptotic/necrotic cell populations. Reovirus/docetaxel combined therapy led to reduced tumour growth and
increased survival in a PC3 tumour bearing mouse model. Microtubule stabilization was enhanced in PC3 cells
treated with reovirus/docetaxel combined therapy compared to other reovirus/chemotherapy combinations.
Conclusions: The co-administration of a variety of chemotherapeutic agents with live reovirus was able to
enhance cytotoxicity synergistically in vitro. The combination of docetaxel with reovirus also delayed tumour
growth and improved survival in vivo. Enhanced microtubule stabilisation following this combination treatment
may, in part, explain the mechanism of synergy. These results provide evidence to support the ongoing clinical
trials using these agents.
Background
Reoviruses (Respiratory Enteric Orphan viruses) are non-
enveloped icosahedral viruses with a segmented double
stranded RNA genome. Reoviruses are ubiquitous, non-
pathogenic viruses that have innate oncolytic activity in a
wide range of human and murine tumour cells. This
property correlates with the transformed state of the cell
[1,2] as transformation of immortalized cells which were
not tumorigenic in vivo with oncogenes such as Ras, Sos,
v-erb and c-myc rendered them susceptible to reovirus
oncolysis [3-5]. In normal cells, activation of double-
stranded RNA-activated protein kinase system (PKR)
prevents significant viral replication; in malignant cells
with an activated Ras pathway, up-regulated upstream or
downstream components of the cell signaling pathway or
up-regulated epidermal growth factor receptor signaling
[3,4,6], this cellular antiviral response mechanism is per-
turbed and viral replication occurs leading to cytolysis of
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the host cell. In view of the high frequency of Ras dysre-
gulation in different cancers [7], reovirus has potential as
a broadly applicable anti-cancer therapeutic. A number
of phase I clinical studies of intratumoral or systemic reo-
virus as a single agent have been completed, with evi-
dence of significant antitumor activity [8,9]. However, in
order to maximise the efficiency of tumour kill, combina-
tion therapy with other treatment modalities such as
radiation or chemotherapy is likely.
Prostate cancer is one of the most common types of
cancer in men, accounting for approximately 24% of
new diagnoses and 13% of cancer deaths in the UK [10].
Surgery and radiotherapy may be curative, but signifi-
cant numbers of patients relapse or present with locally
advanced or metastatic disease and are treated with hor-
monal therapy. However, most subsequently progress
and are treated with further hormonal therapy or
chemotherapy.
Following several reports of significant activity in pros-
tate cancer [11,12], docetaxel (taxotere) has become the
standard of care first line chemotherapy agent worldwide.
Docetaxel is a member of the taxane family and binds
with high affinity to tubulin in microtubules, stabilising
the microtubule and preventing depolymerisation
[13-15]. Mitotic cell division is inhibited by the decrease
in free tubulin, and the accumulation of microtubules
within the cell leads to the initiation of apoptosis.
Reoviruses have been shown to associate with microtu-
bules [16] via the core protein μ2 [17] and it has been
proposed that efficient reovirus growth in some cell types
may be dependent on μ2-mediated recruitment of viral
factories to microtubules [18]. The stabilisation of micro-
tubules by docetaxel could be expected to facilitate reo-
virus replication and enhance the therapeutic potential of
the combination.
In this study we have examined the potential for syner-
gistic or additive anticancer effects of combining reovirus
with docetaxel in human prostate cell lines. We report
this combination leads to enhanced cell death in vitro
and reduced tumour growth in vivo providing evidence
to support the ongoing clinical trials using these agents
together.
Methods
Cell lines
The human prostate cancer-derived cell lines PC3, Du
145 and LNCaP were cultured in RPMI 1640 medium
(Sigma-Aldrich, Gillingham, UK) at 37°C and 5% CO2.
L929, a murine fibroblast-like line, was cultured in
DMEM medium (Sigma-Aldrich) at 37°C and 5% CO2.
All media were supplemented with 2 mM GlutaMAX-1
supplement (Invitrogen, Paisley, UK), 100 units/mL
penicillin/streptomycin (Sigma-Aldrich) and either 10%
(v/v) foetal calf serum (FCS; Invitrogen) for routine pas-
sage or 2% (v/v) FCS for experimental work.
Reovirus stocks and chemotherapeutic agents
Reovirus type 3 Dearing strain Reolysin® was obtained
from Oncolytics Biotech. Inc. (Calgary, Canada). Virus
stock titre and virus stability was measured by standard
plaque assay of serially diluted samples on L929 cells. Six-
well plates were seeded with 1 × 106 L929 cells per well
and infected with dilutions of viral stocks. After 3 h incu-
bation at 37°C, the virus solution was removed and the
wells were overlaid with a 1:1 mixture of 2% SeaPlaque
agarose (Cambrex Bio Science Rockland, Inc, ME) and 2 ×
MEM (Invitrogen) supplemented to a final concentration
of 5% (v/v) FCS, 100 units/mL penicillin/streptomycin and
2 mM GlutaMAX-1. Wells were stained with 500 μL
0.03% neutral red (Sigma-Aldrich) in PBS 72 h post-
infection and plaques were counted 3 to 4 h later.
Docetaxel (Sanofi-Aventis), paclitaxel (Bristol-Myers
Squibb Company, N.Y.), vincristine sulphate (Tocris
Bioscience) and cisplatin (cis diamminedichloroplati-
num; Mayne Pharma Plc, UK) were all obtained from
Royal Surrey County Hospital pharmacy. Doxorubicin
hydrochloride was purchased from Sigma-Aldrich.
In vitro survival assay
Cells were plated in 96-well plates at a density of 5 × 103
cells per well for PC3 and 7.5 × 103 cells per well for Du
145 and LNCaP. After 24 h, they were infected with
known dilutions of reovirus, either alone or in combina-
tion with a chemotherapeutic agent. Control wells
received an equivalent volume of assay medium. After
48 h incubation, cell viability was quantified using the
CellTiter 96 AQueous One Solution Cell Proliferation
Assay reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS;
Promega, Southampton, UK) according to manufacturer’s
instructions. Briefly, 20 μL of MTS reagent was added to
each well and following incubation at 37°C for 1-4 h,
absorbance was measured at 490 nm. Survival was calcu-
lated as a percent compared to untreated cells.
In vitro synergy assay
The effect of the combination of reovirus and che-
motherapy on cell proliferation was assessed by calculat-
ing combination-index (CI) values using CalcuSyn
software (Biosoft, Ferguson, MO). Derived from the
median-effect principle of Chou and Talalay [19], the CI
provides a quantitative measure of the degree of interac-
tion between two or more agents. A CI of 1 denotes an
additive interaction, >1 antagonism and <1 synergy.
Experiments were performed as described for the in
vitro survival assay using 4, 2, 1, 0.5 and 0.25 times the
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calculated median effective dose (ED50) of each agent in
a constant ratio checkerboard design.
Inactivation of reovirus by UV-irradiation and heat
Reovirus was UV inactivated by exposing 50 μL aliquots of
viral stock at 1.2 × 1010 pfu/mL to 720 millijoules irradia-
tion using a Stratalinker UV Crosslinker 2400 (Stratagene,
LA Jolla, CA) to cross link viral RNA. Heat inactivation
was performed by heating 200 μL aliquots of viral stock at
1 × 109 pfu/mL for 20 min at 60°C. In vitro survival and
synergy assays with docetaxel were performed as described
above using PC3 cells to compare the activity of inacti-
vated virus to live virus.
In vivo studies
All procedures were approved by United Kingdom Home
Office (PL70/6521) and institutional boards. Mice were
purchased from B&K Universal Ltd. The experiment was
repeated three times, using six mice in each treatment
group. Subcutaneous tumours were established in the
flank of each mouse by injecting 1 × 107 PC3 cells in a
volume of 100 μL Hanks Balanced Salt Solution (HBSS;
Sigma-Aldrich). Animals were examined thrice weekly
for tumour development. Three orthogonal tumour dia-
meters (d1, d2, and d3) were measured using Vernier cal-
lipers and tumour volume was calculated from the
formula V = π/6 d1·d2·d3. Animals were killed when
tumour size exceeded 15 mm in any one dimension.
Once tumours were established and palpable, mice were
randomly assigned to treatment groups and treated on
days 0 and 3 with either reovirus or docetaxel alone or as
a combined therapy. Reovirus (1 × 108 pfu in 100 μL
volume) was administered using a single cutaneous punc-
ture site. Once in a s.c. location, the 25-gauge needle was
redirected along multiple tracks within the tumour to
achieve maximal dispersal of the reovirus. Docetaxel
(5 mg/kg) was administered intraperitoneally in a total
volume of 100 μL. Vehicle control injections of 100 μL
HBSS were administered in an identical manner to ani-
mals receiving single agent therapy and to control animals.
FACS analysis of cell survival and apoptosis
Following overnight seeding, PC3 cells were treated with
20 nM docetaxel and/or reovirus MOI 1 for 48 h. Adher-
ent and non-adherent cells were collected, washed in cold
PBS, re-suspended at 1 × 106 in 500 μL PBS and then
incubated for 15 min at room temperature in the dark in
cold 1 × binding buffer containing Annexin V-FITC anti-
body, according to manufacturer’s instructions (Merck
Biosciences Ltd). The cells were pelleted and re-suspended
in cold 1 × binding buffer. Cells were stained with 10 μL
propidium iodide (PI) at 30 μg/mL and analysed on a
Coulter Epics XL flow cytometer (Beckman Coulter) using
EXPO32 ADC software (Beckman Coulter).
Measurement of microtubule stability by Western blot
analysis
PC3 cells were seeded overnight at 3 × 106 cells in 10 mL
media in 10 cm Petri dishes and then treated with 5 nM
docetaxel, reovirus at MOI 1, both, or neither for 48 and
72 h. Cells were washed twice in cold PBS and lysed in
500 μL cold RIPA buffer (Thermo Scientific) containing
5 μL of each of Halt protease inhibitor cocktail, phospha-
tase inhibitor cocktail and EDTA (Thermo Scientific). The
samples were incubated on ice for 5 min prior to shearing
of DNA by 3 to 4 passes through a 21ga needle. The sam-
ples were clarified by centrifugation and the supernatant
was transferred to clean tubes and stored at -80°C prior to
analysis by Western blot. Additional samples were col-
lected from PC3 cells treated with paclitaxel (3.5 nM), cis-
platin (1.25 μM), vincristine (40 nM) or doxorubicin
(125 nM) alone or in combination with reovirus for 48 h.
Total protein (5 μg) was electrophoresed on 10% Bis-Tris
gels (Invitrogen), transferred to polyvinylidene difluoride
membranes, blocked, and exposed overnight to a mouse
monoclonal acetylated a-tubulin primary antibody (6-11B-
1, 1:30,000; Sigma-Aldrich) or mouse a-tubulin antibody
(B-5-1-2, 1:50,000; Sigma-Aldrich) followed by incubation
with a horseradish peroxidase labelled secondary antibody.
Signal was developed using an Enhanced Chemilumines-
cence Plus Detection System (Amersham, UK).
Effect of low-dose docetaxel on virus production
PC3 cells were infected with reovirus (MOI 1) alone or
in combination with 5 nM docetaxel. Samples were col-
lected at 24, 48, 72 and 96 h post infection and follow-
ing three cycles of freeze-thaw, were tested for viral titre
by plaque assay of 10-fold serial dilutions on L929 cells.
Statistical analysis
Comparisons between groups were done using the 2-sided
t-test and 2-way ANOVA. Statistical analysis was per-
formed using GraphPad Prism 4 (GraphPad Software Inc.).
Results
Reovirus cytotoxicity in PC3, Du 145 and LNCaP cell lines
The effect of reovirus infection over 48 h was assessed
in three human prostate cancer cell lines. Cells were
infected with doubling dilutions of reovirus from MOI
10 or 100. Differential sensitivity to reovirus across the
cell lines was observed (Figure 1). PC3 cells were the
most sensitive to reovirus induced cell death whereas
Du 145 cells were the most resistant.
Reovirus cytotoxicity is enhanced by combination with
docetaxel
Using the data obtained above, the median effective
dose (ED50) i.e. one at which half the test cells were
killed at a given time point was calculated for reovirus.
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An ED50 for docetaxel was established in the same
manner. PC3 and Du 145 cells, being the most and least
susceptible cell lines respectively, were chosen for
further study and treated with either reovirus or doce-
taxel alone, or in combination, at doses representing 4,
2, 1, 0.5 and 0.25 times the calculated ED50 in a con-
stant ratio checkerboard design (Figure 2). An MTS sur-
vival assay was performed after 48 hours. The
combination of agents enhanced tumour kill compared
to each agent alone.
Synergistic interaction between reovirus and
chemotherapeutic agents in PC3 and Du 145 prostate
cancer cell lines
From this data we calculated combination indices (CI)
and used isobologram analysis to determine whether
this enhancement of cell death could be considered
synergistic. The CI provides a quantitative measure of
the degree of interaction between two or more agents.
A CI of 1 denotes an additive interaction, >1 antagon-
ism and <1 synergy.
The combination of reovirus and docetaxel on PC3
cells was shown to be highly synergistic at the ED50
(Table 1), but becoming mildly antagonistic as the doses
were increased. In contrast, on Du 145 cells, the combi-
nation proved to be additive at the ED50 (Table 2),
becoming increasingly synergistic as the dose was
increased.
We then evaluated the effect of other chemotherapeu-
tic agents on these two cell lines (Tables 1 and 2), look-
ing at paclitaxel (another taxane), vincristine (a
microtubule inhibitor), cisplatin (a pseudo-alkylating
agent) and doxorubicin (a DNA intercalating agent).
We observed synergistic cell kill with all agents, how-
ever CI values were slightly lower in PC3 cells than in
Du 145.
Live virus is required for efficient cell killing
Aliquots of reovirus were exposed to heat or UV irradia-
tion to inactivate the virus and then used alongside live
virus in an MTS survival assay using PC3 cells. Live virus
resulted in the most efficient cell kill, ranging from 80 to
36% survival at the MOIs used. This effect was markedly
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Figure 1 Differing sensitivities of prostate lines to reovirus
infection. Prostate cell lines PC3 (diamonds), LNCaP (squares) and
Du 145 (triangles) were infected with reovirus type 3 Dearing strain
Reolysin at the indicated MOI for 48 h. Cell survival at this time was
determined using MTS assay. Data are normalized to the uninfected
control (MOI 0) for each cell line and are representative of three
independent experiments.
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Figure 2 Reovirus induced cell kill is enhanced by the addition
of docetaxel. PC3 (a) and Du 145 cells (b) were treated with
reovirus alone (diamonds), docetaxel alone (squares) or a
combination of the two (triangles) at the doses indicated for 48 h.
Survival was measured at this time using MTS. In both cell lines
tested, the combined treatment significantly reduced cell survival
compared to either treatment alone (2-way ANOVA, p < 0.0001).
Table 1 Interaction of reovirus and chemotherapy on
PC3a
Chemotherapeutic ED50 ED75 ED90
Docetaxel 0.41 ± 0.07 0.75 ± 0.04 1.58 ± 0.08
Paclitaxel 0.57 ± 0.01 0.40 ± 0.03 0.31 ± 0.04
Vincristine 0.46 ± 0.06 0.34 ± 0.05 0.44 ± 0.11
Cisplatin 0.89 ± 0.06 0.51 ± 0.07 0.33 ± 0.05
Doxorubicin 0.49 ± 0.03 0.22 ± 0.03 0.11 ± 0.03
adata is presented as combination index values ± SEM of three independent
experiments at the effective dose indicated/
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reduced when the same MOI of UV-inactivated virus was
used, and almost completely negated by heat inactivated
virus (Figure 3a).
Live, heat inactivated and UV-inactivated reovirus was
combined with docetaxel at a fixed ratio of 60 nM doc-
etaxel to MOI 1 reovirus over five two-fold dilutions
for 48 hours. The combination of live reovirus with
docetaxel enhanced cell kill compared to docetaxel
alone (2-way ANOVA p < 0.0001). This enhancement
of cell kill was not apparent when heat inactivated or
UV-inactivated reovirus was used (Figure 3b)
Combined reovirus and docetaxel treatment delays
tumour growth in a PC3 xenograft murine model
In light of the observed in vitro synergy, the effects of
combined reovirus and docetaxel on PC3 cells were
evaluated in vivo in a nude mouse model. PC3 cells (1 ×
107) were implanted subcutaneously in the flanks of
nude mice and treatment was initiated when tumours
reached an average diameter of 3 mm. Mice were trea-
ted with intratumoral reovirus, intraperitoneal docetaxel
or both on day 0 and day 3. Control mice received the
same tumour inoculum and were treated with an
equivalent volume of HBSS i.t. and i.p. administered in
an identical manner. There were no obvious toxic effects
of single agent or combination treatments in all mice
treated, and experiments were concluded as a result of
tumour growth reaching 15 mm in any one dimension.
The combination of docetaxel and reovirus resulted in
the most effective response in terms of tumour growth
retardation (p < 0.001, day 11, Figure 4), although reo-
virus monotherapy also resulted in delayed tumour
Table 2 Interaction of reovirus and chemotherapy on Du
145a
Chemotherapeutic ED50 ED75 ED90
Docetaxel 1.02 ± 0.05 0.83 ± 0.03 0.75 ± 0.07
Paclitaxel 0.89 ± 0.06 0.70 ± 0.08 0.58 ± 0.10
Vincristine 0.80 ± 0.01 0.57 ± 0.05 0.44 ± 0.08
Cisplatin 0.74 ± 0.13 0.61 ± 0.06 0.52 ± 0.06
Doxorubicin 0.82 ± 0.03 0.69 ± 0.03 0.59 ± 0.06
adata is presented as combination index values ± SEM of three independent
experiments at the effective dose indicated.
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Figure 3 Live virus is required for efficient cell kill and
enhanced cell kill with docetaxel. PC3 cells were treated with live
(diamonds), heat-inactivated (squares), or UV-inactivated (triangles)
virus for 48 h at the MOI indicated at which point survival was
measured by MTS assay (a). PC3 cells were also treated with
docetaxel alone (diamonds), or docetaxel with live reovirus
(squares), heat-inactivated reovirus (triangles) or UV-inactivated virus
(crosses) for 48 h at the concentration and MOI indicated. Survival
was measured at this time by MTS assay. The combination of live
reovirus with docetaxel enhanced cell kill compared with docetaxel
alone (P < 0.0001, two-way ANOVA), however this enhancement of
cell kill was not apparent when heat inactivated or UV-inactivated
reovirus was used (b). Data for both are normalized to uninfected
controls (MOI 0) and are representative of three independent
experiments.
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Figure 4 Reduced tumour growth and increased survival
following reovirus/docetaxel combination therapy. Nude mice
bearing subcutaneous PC3 tumours were treated on days 0 and 3
with either 1 × 108 pfu reovirus alone i.t. (diamonds), 5 mg/kg
docetaxel alone i.p. (squares), or reovirus and docetaxel in
combination (triangles). Control treated mice (circles) and single
therapy treated mice received equivalent HBSS vehicle control
injections. Tumours were measured on the days indicated and
tumour volume expressed as tumour volume relative to volume at
commencement of treatment. Docetaxel alone had no effect on
tumour volume compared to control treatment (p > 0.05). Reovirus
alone had a moderate effect (p < 0.05 day 9 and p < 0.001 day 11),
but the greatest effect was when reovirus therapy was combined
with docetaxel (p < 0.05 day 8, p < 0.01 day 9 and p < 0.001 day
11). Mice were euthanized when tumours exceeded 15 mm in any
one dimension. Data shown are representative of three
independent experiments.
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growth (p < 0.001, day 11). Docetaxel monotherapy
however had no effect on tumour growth at this dose
(p > 0.05).
Enhanced apoptotic cell death with docetaxel and
reovirus combination
We wished to investigate further the nature of the
synergy of cell kill with reovirus and docetaxel treat-
ment. The mode of cell death of PC3 cells treated with
reovirus MOI 1, docetaxel 20 nM or both agents
together was assessed at 24 and 48 h by annexin/PI
staining. At 24 hours, there was a small increase in late
apoptotic/necrotic population (A+PI+) in all groups, but
slightly more so in the combination. By 48 h, this effect
had increased considerably with the majority of cells in
the combination group A+PI+ and concomitant reduc-
tion of intact cells (A-PI-). The effect of reovirus alone
also caused a degree of apoptotic death in this cell line
(Figure 5a and 5B).
Increased acetylation of microtubules following exposure
to reovirus and docetaxel
Docetaxel is known to enhance microtubule stability,
ultimately leading to apoptotic cell death. The acetylation
of a-tubulin may be used as a marker of microtubule sta-
bility, with the amount of acetylated a-tubulin being pro-
portional to the stability of the microtubule. We wished
to determine if the combination of reovirus and docetaxel
had any enhancement of effect on acetylated a-tubulin
expression compared to each agent alone. Protein sam-
ples from PC3 cells were collected at 48 and 72 h after
treatment with docetaxel or reovirus alone or in combi-
nation. Treatment with docetaxel alone led to a substan-
tial increase in acetylated a-tubulin compared to
untreated cells at both time points. An increase in acety-
lated a-tubulin was also observed in samples from cells
infected with reovirus alone. Docetaxel in combination
with reovirus led to the greatest increase, suggesting an
additive or possibly synergistic effect (Figure 6a). We
then looked at the effect of other chemotherapeutic
agents on acetylated a-tubulin induction in PC3 cells.
Background levels of acetylated a-tubulin were detected
following exposure to cisplatin and doxorubicin. Expo-
sure to paclitaxel and vincristine (both know to stabilise
microtubules) resulted in an above background level of
acetylated a-tubulin. When combined with reovirus how-
ever, only cells exposed to the paclitaxel/reovirus
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Figure 5 Enhanced apoptotic cell death of PC3 cells treated
with reovirus and docetaxel in combination. PC3 cells were
treated with reovirus MOI 1 (open bars), 20 nM docetaxel (wide
diagonal stripes) or both agents together (narrow diagonal stripes)
for 24 h (a) or 48 h (b) before staining with Annexin V (A) and
propidium iodide (PI) and analysing using flow cytometry. Untreated
cells (dark grey bars were included as a negative control). Addition
of each agent alone resulted in an increased late apoptotic/necrotic
population (A+/PI+) and concomitant reduction of intact cells
(A-/PI-) compared to untreated cells. There was a dramatic increase
in this effect at 48 h when the two agents were combined.
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Figure 6 Enhanced stabilisation of microtubules. PC3 cells were
treated with docetaxel (D) or reovirus (R), alone or in combination
(R+D) for 48 or 72 h (a) and levels of a-tubulin and acetylated a-
tubulin were assessed by Western blot. Both treatments alone led
to an increase in acetylated a-tubulin compared to untreated cells
(C). When applied in combination, there was an even greater
increase. Levels of acetylated a-tubulin increased for each treatment
in a time dependent manner. Protein samples were additionally
collected at 48 h post treatment from PC3 cells treated with
paclitaxel (P), doxorubicin (Dox), cisplatin (Cis) and vincristine (V) and
assessed in the same way (b). Treatment with paclitaxel and
vincristine led to an increase in acetylated a-tubulin above
untreated cells, whereas treatment with doxorubicin and cisplatin
did not. Only treatment with paclitaxel in combination with reovirus
produced levels of acetylated a-tubulin greater than that of reovirus
infection alone.
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combination exhibited levels of acetylated a-tubulin
greater than following exposure to reovirus alone
(Figure 6b).
Increased viral titre at early time points from cells
exposed to reovirus and docetaxel compared to reovirus
alone
Samples were collected at 24, 48, 72 and 96 h post
infection from PC3 cells infected with reovirus in asso-
ciation with low dose docetaxel and virus titre was
determined by plaque assay. A higher titre was recov-
ered at earlier time points from cells treated with doce-
taxel and reovirus compared to cells infected with
reovirus alone. By 72 h post infection however, there
was no difference in titre and at 92 h post infection,
while the titre in reovirus only samples continued to
increase, it was decreasing in samples collected from
cells treated with both agents (Figure 7).
Discussion
The modest improved survival with docetaxel che-
motherapy in recent studies has been a significant step
forward in the treatment of hormone refractory meta-
static prostate cancer (HRPC) but the overall poor prog-
nosis and morbidity justifies the continued development
of new treatment approaches [11,12]. Although a num-
ber of oncolytic viruses have shown significant anti-
tumour effects in phase I clinical studies [8,9,20,21],
their potential as main stream anti-cancer therapeutics
will most likely be realised as combination therapy with
other cancer treatment modalities. Theoretically, combi-
nation therapy could potentially allow reovirus to target
drug or radiotherapy resistant subpopulations of tumour
cells, or chemotherapy could be utilised to improve the
biodistribution of oncolytic viruses.
In this study, we have demonstrated evidence of
synergistic anti-cancer activity of oncolytic wild type
reovirus with docetaxel in human prostate cancer in
vitro and in vivo. In vitro synergy was further observed
with other chemotherapeutic agents. The potential value
of reovirus in combination with docetaxel was tested in
a murine flank model of human prostate cancer. We did
not observe any toxic effects in the treatment groups
and while docetaxel alone had little effect on tumour
progression at the dose used, reovirus alone had a mod-
est effect. In combination however, there was significant
inhibition of tumour progression.
Docetaxel and other members of the taxane family of
chemotherapeutic drugs have been shown to stabilise
microtubules in mitotic cells. Microtubules are essential
for the separation of the duplicated chromatids to
opposing poles prior to mitotic cell division. Stabilisa-
tion of microtubules impairs normal changes in micro-
tubule structure, leading to a block in mitosis and
promotion of apoptosis [22,23]. The reoviral μ2 protein
is an approximately 83 kDa protein encoded by the M1
genome segment. It forms a structurally minor compo-
nent of the reovirus core and binds ssRNA and dsRNA
[24-27]. It is also capable of binding to cellular microtu-
bules [17,28,29]. It has been proposed that for some cell
types, μ2-mediated recruitment of viral factories to
microtubules might be necessary for efficient reovirus
growth [18]. We proposed that the presence of another
agent also stabilising microtubules, could enhance these
effects. We found that PC3 cells treated with reovirus in
combination with docetaxel exhibited a considerable
increase in microtubule acetylation compared to
untreated or single agent treated cells. The same effect
was observed with paclitaxel but not with doxorubicin
or cisplatin which do not alter microtubule stability.
Interestingly we found no enhancement of microtubule
stability with vincristine, but this can be explained by
the known mechanisms of action of the vinca alkaloids
on tumour cells. The vinca alkaloids, such as vinblastine,
vincristine, and vinorelbine, bind to the end of growing
microtubules, blocking the addition of more tubulin
dimers. The tubule cannot grow, but it can still disas-
semble, so the microtubules ultimately break down. The
inhibition of tubular growth by vincristine would there-
fore not allow microtubule stabilisation, reovirus adher-
ence and reoviral replication. However, our in vitro
studies showed that the combination of vincristine and
reovirus still resulted in synergistic cell kill suggesting
some alternative mechanism. These findings provide
further evidence of multiple mechanisms by which reo-
virus may combine with other anti-cancer treatments to
enhance its antitumour effects. This broadens the poten-
tial clinical utility of reovirus very greatly. Although the
data from PC3 cells was most compelling in terms of
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Figure 7 Effect of low-dose docetaxel on viral production in
PC3 cells. PC3 cells were infected with reovirus at MOI 1 alone
(diamonds) or in combination with 5 nM docetaxel (squares).
Triplicate samples were collected at the time points indicated and
virus amount determined by plaque assay.
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synergy by CI, we did see evidence of at least additive
effects in DU145 with docetaxel and synergy with pacli-
taxel rather than antagonism. It would be important to
evaluate the in vivo effects of combination with vincris-
tine and paclitaxel to confirm the in vitro findings in
future work. There would also be an opportunity to
assess post-treatment tissue for reovirus replication and
microtubule protein expression to compare our in vitro
findings
In this study, we found an increase in viral titre at
early time points in cells treated with the combined
therapy. This has been noted previously for various
non-small cell lung cancer cell lines treated with pacli-
taxel in combination with reovirus [30]. At later time
points, as the cells treated with docetaxel and reovirus
became apoptotic and necrotic, the amount of virus
recovered fell to levels less than from cells infected with
reovirus alone.
Other chemotherapy/oncolytic virus combinations
have also shown considerable promise. Recently,
G47delta, an engineered oncolytic herpes simplex virus-1
was shown to have synergistic antitumour effects in vitro
and in vivo in combination with taxanes through the
enhancement of apoptosis [31]. The adenovirus Onyx-
015 enhanced clinical efficacy when used as intratumoral
injection combined with systemic cisplatin and 5-fluor-
ouracil (5FU) compared to chemotherapy alone [32]. In
preclinical models, synergy has been demonstrated with
the combination of E1A-expressing adenoviral E3B
mutants with cisplatin and paclitaxel [33], rat parvovirus
H-1PV with gemcitabine [34] and oncolytic herpesviruses
such as G207, HSV-1716, and NV1066 with various che-
motherapeutic agents [35-37]. The mechanism underly-
ing the observed synergy is incompletely understood and
as in our study, not necessarily due to increased viral
replication [38-40].
Recently completed phase I studies by our group and
others using Reovirus type 3 (Dearing) have confirmed
its potential as an anticancer agent as well as its safety
and tolerability in humans [8,9]. This has led to combina-
tion studies of systemic reovirus with a number of che-
motherapeutic agents and radiotherapy as phase I studies
(REO-). These include attempts to enhance cytotoxicity
with gemcitabine (REO 09), docetaxel (REO10) and car-
boplatin/paclitaxel (REO11, REO15 and REO16) in a
number of indications. The REO10 study showed the
reovirus/docetaxel combination was safe and a maximum
tolerated dose was not reached. Antitumor activity was
seen with one complete response and three partial
responses. A disease control rate (combined complete
response, partial response, and stable disease) of 88% was
observed. Immunohistochemical analysis of reovirus pro-
tein expression was observed in post-treatment tumor
biopsies from three patients [41].
Conclusions
Reovirus has a potentially broad application as an anti-
cancer therapeutic and oncolytic activity has been demon-
strated in vitro, in in vivo murine models and in early clin-
ical trials. Administration in combination with other
modalities such as chemotherapy, targeted therapy and
radiotherapy may be necessary in order to realize the full
potential of reovirus, and indeed other oncolytic viruses.
We have demonstrated here and elsewhere [42] that co-
delivery of reovirus with chemotherapeutic agents with a
variety of modes of actions is able to enhance in vitro cyto-
toxicity in a synergistic manner. Our focus here was the
interaction of reovirus with docetaxel, the standard of care
first line chemotherapy agent for prostate cancer, on the
highly metastatic human prostate cell line PC3. We showed
that the combination therapy was synergistic in vitro, it was
capable of slowing tumour growth and prolonging survival
in a PC3 tumour mouse model. Microtubule stabilisation
was enhanced in PC3 cells following treatment with com-
bined reovirus/docetaxel combined therapy which may, in
part, explain the mechanism of synergy. This data supports
the positive clinical observations from the recent REO10
docetaxel/reovirus combination study.
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